US Patent

US10561659 — Treatment of hair loss disorders with deuterated JAK inhibitors

Method of Use · Assigned to Concert Pharmaceuticals Inc · Expires 2037-05-04 · 11y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of treating hair loss disorders by administering a specific amount of deuterated JAK inhibitor, deuruxolitinib phosphate.

USPTO Abstract

Disclosed is a method of treating in a subject hair loss disorders that are beneficially treated by administering a JAK1 and/or JAK2 inhibitor. The method comprises administering to the subject an amount in the range of about 4 mg to about 50 mg of Compound (I), or a pharmaceutically acceptable salt thereof. This invention also provides compositions comprising Compound (I) and the use of such compositions in the described methods.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3976 — deuruxolitinib-phosphate

Patent Metadata

Patent number
US10561659
Jurisdiction
US
Classification
Method of Use
Expires
2037-05-04
Drug substance claim
No
Drug product claim
No
Assignee
Concert Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.